Long-term cause-specific mortality of patients treated for Hodgkin's disease.
暂无分享,去创建一个
H. Bartelink | F. V. van Leeuwen | B. Aleman | A. W. van den Belt-Dusebout | M. V. van't Veer | W. J. Klokman
[1] P. Davis,et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Stovall,et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Neuberg,et al. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Friedberg,et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] John D Boice,et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. , 2002, Journal of the National Cancer Institute.
[6] R. Greil,et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Masala,et al. The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. , 2001, International journal of radiation oncology, biology, physics.
[8] M. Williams,et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Aeppli,et al. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. , 2000, International journal of radiation oncology, biology, physics.
[10] P. Goss,et al. Breast cancer risk following irradiation for Hodgkin's disease. , 2000, Cancer treatment reviews.
[11] H. Storm,et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] F. Berger,et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial. , 2000, Blood.
[13] D. Neuberg,et al. Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] T. Lister,et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Hagenbeek,et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] I. Alvarado,et al. Second Lethal Events Associated with Treatment for Hodgkin's Disease: A Review of 2980 Patients Treated in a Single Mexican Institute , 2000, Leukemia & lymphoma.
[17] V. Diehl,et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R Peto,et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Noordijk. Radiotherapy in early stage Hodgkin's disease: principles and results of recent clinical trials. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] P. Goss,et al. Current perspectives on radiation-induced breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Connors,et al. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Willett,et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease , 1997, Cancer.
[23] S. Hancock,et al. Gastrointestinal cancer after treatment of Hodgkin's disease. , 1997, International journal of radiation oncology, biology, physics.
[24] J. Raemaekers,et al. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Cu , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] A. Horwich,et al. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. , 1997, British Journal of Cancer.
[26] Hancock,et al. Long-Term Complications of Treatment and Causes of Mortality After Hodgkin's Disease. , 1996, Seminars in radiation oncology.
[27] L. Robison,et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. , 1996, The New England journal of medicine.
[28] M. Siimes,et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. , 1996, European journal of cancer.
[29] N. Willich,et al. Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. , 1996, International journal of radiation oncology, biology, physics.
[30] A. Hagenbeek,et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. , 1995, Journal of the National Cancer Institute.
[31] L. Kalish,et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. , 1995, The cancer journal from Scientific American.
[32] M. Hudson,et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] T. Miller,et al. Low-Dose Involved Field Radiation after Chemotherapy in Advanced Hodgkin Disease: A Southwest Oncology Group Randomized Study , 1994, Annals of Internal Medicine.
[34] A. Hagenbeek,et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Hagenbeek,et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] A. Hagenbeek,et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] U. Tirelli,et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] D. Linch,et al. Late mortality in young BNLI patients cured of Hodgkin's disease. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] K. Maclennan,et al. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. , 1993, British Journal of Cancer.
[40] S L Hancock,et al. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. , 1993, JAMA.
[41] J. Lubin,et al. Coronary artery disease mortality in patients treated for hodgkin's disease , 2010, Cancer.
[42] P. Steinherz,et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.
[43] J. Cosset,et al. Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience , 1991 .
[44] E. Noordijk,et al. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. , 1990, International journal of radiation oncology, biology, physics.
[45] N. Day,et al. Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.
[46] B. Hancock,et al. Immunity in Hodgkin's disease: status after 10 years remission. , 1982, British Journal of Cancer.
[47] S. Hancock,et al. Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. , 1988, Annals of internal medicine.
[48] P. Mazza,et al. Treatment‐related leukemia in Hodgkin's disease: A multi‐institution study on 75 cases , 1987, Hematological oncology.
[49] R. Hoover,et al. Leukemia after therapy with alkylating agents for childhood cancer. , 1987, Journal of the National Cancer Institute.
[50] J. Boivin,et al. Coronary heart disease mortality after irradiation for Hodgkin's disease , 1982, Cancer.
[51] R. Fisher,et al. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. , 1980, Annals of internal medicine.
[52] Z. Fuks,et al. The long term effects of radiation on T and B lymphocytes in the peripheral blood after regional irradiation , 1977 .